W
WAVEMAN · COMPANY
CVSI · Cv Sciences, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-6.94% 13F +440META-0.53% 13F +2,698RCG+2.79% CLUSTERUTHR+2.12% 13F +424CRWV+11.72% 13F +693CRM-3.90% 13F +1,020CVNA+0.17% 13F +795TPL+5.37% 13F +443DELL+1.86% 13F +1,204NET+1.93% 13F +711MSTR-4.40% 13F +526CRWD-1.45% 13F +1,383ANET-1.04% 13F +1,324COIN-3.09% 13F +475TEAM-6.94% 13F +440META-0.53% 13F +2,698RCG+2.79% CLUSTERUTHR+2.12% 13F +424CRWV+11.72% 13F +693CRM-3.90% 13F +1,020CVNA+0.17% 13F +795TPL+5.37% 13F +443DELL+1.86% 13F +1,204NET+1.93% 13F +711MSTR-4.40% 13F +526CRWD-1.45% 13F +1,383ANET-1.04% 13F +1,324COIN-3.09% 13F +475
← ALL COMPANIES

CVSI

CV Sciences, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001510964
SEC FILINGS☆ WATCH
INSIDER NET · 180D
$114.8K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
1
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
0
13F, latest reported quarter
REVENUE GROWTH
-12.2%
XBRL, annual
NET MARGIN
-6.9%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$114.8K over 180 days
+$114.8K over 90 days · +$114.8K of it by a 10%+ holder
more than 77% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
fewer than five institutions report holding it
REVENUE
-12.2% year over year
below 71% of Pharma & Biotech
MARGIN
-6.9% net margin
more than 58% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
<0.1% of shares outstanding short · 1.0 days to cover · settled 2026-08-14
below 92% of Pharma & Biotech
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -33.3%
-33.3%12M
-33%+44%+122%+200%2025-092025-112026-012026-032026-052026-07 2026-07-28 · CHEEVER CHARLIE E III bought $36.6K2026-07-31 · CHEEVER CHARLIE E III bought $34.6K2026-07-17 · CHEEVER CHARLIE E III bought $15.0K2026-07-24 · CHEEVER CHARLIE E III bought $9.4K2026-07-21 · CHEEVER CHARLIE E III bought $6.7K2026-07-22 · CHEEVER CHARLIE E III bought $5.5K2026-08-04 · CHEEVER CHARLIE E III bought $2.2K2026-08-07 · CHEEVER CHARLIE E III bought $1.9K2026-07-16 · CHEEVER CHARLIE E III bought $1.8K2026-07-29 · CHEEVER CHARLIE E III bought $1.2K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders are net buyers of their own stock.
The record shows a net $114.8K bought by insiders over 180 days. Every figure is a federal filing, dated the day it became public.
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, CV Sciences, Inc. insiders bought a net $114.8K of stock across 10 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-10.

INSIDER
FILED
SHARES
VALUE
CHEEVER CHARLIE E III
BUY
2026-08-07
94,854.0
$1.9K
CHEEVER CHARLIE E III
BUY
2026-08-04
108,000.0
$2.2K
CHEEVER CHARLIE E III
BUY
2026-07-31
1,730,000.0
$34.6K
CHEEVER CHARLIE E III
BUY
2026-07-29
60,000.0
$1.2K
CHEEVER CHARLIE E III
BUY
2026-07-28
1,830,000.0
$36.6K
10 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 5 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported

no 13F holders found for this ticker

SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$419.0K
$423.1K
$308.0K
2024
$457.7K
$241.3K
$343.3K
+0%
2023
$403.2K
$314.0K
$273.0K
+33%
2022
$299.0K
$245.3K
$210.5K
-75%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$13.8M$15.7M$16.0M$16.2M
GROSS PROFIT$6.8M$7.2M$7.1M$5.5M
OPERATING INCOME$-470.0K$-2.2M$3.4M$-6.8M
NET INCOME$-958.0K$-2.4M$3.1M$-8.2M
EPS (DILUTED)-0.01-0.010.02-0.07
OPERATING CASH FLOW$-407.0K$-861.0K$2.3M$-1.9M
CASH$611.0K
LONG-TERM DEBT$387.0K$0
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-10 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-10 ALL SYSTEMS LIVE FOR MACHINES →